If Makowka did in fact leave, I believe is bad news for the liver study. It probably means it did fail and we will never hear a PR of the failure. It will be swept under the rug. Oh well. My hopes were not high on the success of that organ. They have been tinkering with it for years. Can't bat 1.000.
We have other irons in the fire with proven results.
ENDV is exhibiting some of the usual signs when a company is up for sale. - holding pattern - cost controls - sales being pushed - defection of key personnel
News 
Market Data 
Discover 
